Compare Davita Inc (DVA) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Tesla, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Tesla, Inc. trades at $378.52 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 132.1× Davita Inc's market cap, and Davita Inc is more actively traded (650,294 versus 25,496,215). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Tesla, Inc. for 88 Days on average.
| DVA | TSLA | |
|---|---|---|
Market Cap | $11.28B | $1.49T |
Volume | 650,294 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $489.88 |
52-Week Low | $103.87 | $298.16 |
Typical Hold Time | 113 Days | 88 Days |
Enterprise Value | $24.00B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Tesla (TSLA) trades at $375.03, down 1.48% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs $0.50 expected) following two previous beats, with revenue declining to $94.83B in 2025. Analyst sentiment remains divided with 41% buy ratings but a consensus price target of $441.36 suggesting 18% upside. Recent regulatory approval for driver-assistance software in Europe provides near-term catalyst potential.
Tesla faces execution risks amid slowing auto growth but maintains leadership in autonomous driving technology. The stock's premium valuation (P/E 349.82) requires successful expansion into robotics and AI to justify current levels. Near-term pressure from delivery misses contrasts with long-term potential in energy and autonomy markets, creating a high-risk, high-reward investment profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
